Skip to content

Lactobacillus Reuteri in Children With Constipation

The Assessment of Lactobacillus Reuteri Efficacy, Provided With Forlax, as Treatment of Incurable Constipation in Children 3-7 Years. Double Blind, Placebo-controlled, Randomized and Multicenter Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01388712
Enrollment
128
Registered
2011-07-07
Start date
2011-07-31
Completion date
2012-12-31
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Constipation

Keywords

Probiotics, constipation, children

Brief summary

The most common cause of children chronic constipation is functional disorders. Functional constipation is diagnosed after excluding organic causes of constipation (anatomical, neurological, endocrinological) and identification of two symptoms defined by the Rome III criteria. There could be low number of bowel movements (below three times a week), defecation pain, fecal incontinence (once a week), stool consistency or occurrence of large diameter stools. The treatment is change of diet, defecation training and application of laxatives. The probiotics are defined as living microorganisms, which provided in a proper doses should result in beneficial effect on a host health. The assessment of its characteristic is related to strain of bacteria affiliation. Taking into the consideration that patients with constipation may experience microflora intestine disorders, using the probiotics can have the positive impact on process of treating this disease. The additional reason for using the probiotics during the constipation treatment is an influence of probiotics on movement of the alimentary canal. In spite of proved effectiveness of some probiotics' strains further research are required, because clinical significance is ambiguous and the effect is confirmed among patients with short medical history. That's way the further analysis of probiotic Lactobacillus reuteri DSM 17938, which was successful treatment method of chronic constipation amongst children (infants) should be performed. The primary aim of the study is the assessment of Lactobacillus reuteri DSM 17938 efficacy, provided with macrogol (Forlax), as treatment of constipation in 3-7 years old children. The baseline of estimation is the frequency comparison of bowel movement in children belonging into two groups: Lactobacillus reuteri treatment and placebo. The secondary aim of the study is the assessment of frequency the additional symptoms connected with defecation disorders: such as: number of pain episodes during defecation, the intensity of pain, number of hard stools, number of fecal incontinence per week, number of macrogol (Forlax) pockets used. The investigators believe that constipation treatment (laxatives- macrogol) with Lactobacillus reuteri has better efficacy that the same treatment without Lactobacillus reuteri in 3-7 years old children with medical history of chronic constipation.

Interventions

Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10\^8CFU).

DIETARY_SUPPLEMENTPlacebo

Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.

Sponsors

Children's Memorial Health Institute, Poland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
3 Years to 7 Years
Healthy volunteers
No

Inclusion criteria

* Children 3-7 years old * Occurrence less than three bowel movement per week * Medical history from at least two months\] * Ineffective laxative treatment at least two months * The parents approval for child participation in the study and for the treatment

Exclusion criteria

* Well-known, organic cause of constipation (i.e. hypothyroidism, Hirschprung disease, cystis fibrosis) * Anatomic defects of the alimentary canal * The surgery of the alimentary canal in the past * Treatment of antibiotics/probiotics during last two weeks before start of the study

Design outcomes

Primary

MeasureTime frame
Number of bowel movement per week, without fecal incontinence12 weeks

Secondary

MeasureTime frameDescription
The number of pain episodes during defecation per week,12 weeks
The number of hard stools12 weeks
The number of bowel movements per week12 weeksOther secondary items are: the number of pain episodes during defecation per week, the number of hard stools, the number of fecal incontinence per week, the number of patients who have to change amount of drug or use of enema.
The number of patients who have to change amount of drug12 weeks
The number of patients who have to change use of enema.12 weeks
The number of fecal incontinence per week12 weeks

Countries

Poland

Contacts

Primary ContactJaroslaw Kierkus, Ph.D.
+48 228157384

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026